Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant

DOI DOI DOI 機関リポジトリ (HANDLE) HANDLE ほか3件をすべて表示 一部だけ表示 研究データあり 被引用文献15件 参考文献91件 オープンアクセス
  • 齊藤, 暁
    Department of Veterinary Science, Faculty of Agriculture, University of Miyazaki; Graduate School of Medicine and Veterinary Medicine, University of Miyazaki; Center for Animal Disease Control, University of Miyazaki
  • 田村, 友和
    Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University
  • Zahradnik, Jiri
    Department of Biomolecular Sciences, Weizmann Institute of Science; First Medical Faculty at Biocev, Charles University
  • 出口, 清香
    Center for iPS Cell Research and Application (CiRA), Kyoto University
  • 田畑, 耕史郎
    Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido University
  • 安楽, 佑樹
    Laboratory of Biomolecular Science and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University
  • 木村, 出海
    Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo
  • 伊東, 潤平
    Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo
  • 山岨, 大智
    Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo; Faculty of Medicine, Kobe University
  • Nasser, Hesham
    Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus infection, Kumamoto University; Department of Clinical Pathology, Faculty of Medicine, Suez Canal University
  • 豊田, 真子
    Division of Infection and immunity, Joint Research Center for Human Retrovirus infection, Kumamoto University
  • 永田, 佳代子
    Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University
  • 瓜生, 慧也
    Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo; Graduate School of Medicine, The University of Tokyo
  • 小杉, 優介
    Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo; Graduate School of Medicine, The University of Tokyo
  • 藤田, 滋
    Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo; Graduate School of Medicine, The University of Tokyo
  • Shofa, Maya
    Department of Veterinary Science, Faculty of Agriculture, University of Miyazaki; Graduate School of Medicine and Veterinary Medicine, University of Miyazaki
  • Monira Begum, M.S.T.
    Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus infection, Kumamoto University
  • 清水, 凌
    Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus infection, Kumamoto University
  • 小田, 義崇
    Department of Cancer Pathology, Faculty of Medicine, Hokkaido University
  • 鈴木, 理滋
    Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University
  • 伊藤, 駿
    Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University
  • 直, 亨則
    Division of International Research Promotion, International Institute for Zoonosis Control, Hokkaido University
  • 王, 磊
    Department of Cancer Pathology, Faculty of Medicine, Hokkaido University; Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University
  • 津田, 真寿美
    Department of Cancer Pathology, Faculty of Medicine, Hokkaido University; Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University
  • 吉松, 組子
    Institute for Genetic Medicine, Hokkaido University
  • 倉持, 仁
    Interpark Kuramochi Clinic; Department of Global Health Promotion, Tokyo Medical and Dental University
  • 喜多, 俊介
    Laboratory of Biomolecular Science and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University
  • 田畑, 香織
    Department of Medicinal Sciences, Graduate School of Pharmaceutical Sciences, Kyushu University
  • 福原, 秀雄
    Global Station for Biosurfaces and Drug Discovery, Hokkaido University; Division of Pathogen Structure, International Institute for Zoonosis Control, Hokkaido University
  • 前仲, 勝実
    Laboratory of Biomolecular Science and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University; Global Station for Biosurfaces and Drug Discovery, Hokkaido University; Division of Pathogen Structure, International Institute for Zoonosis Control, Hokkaido University
  • 山本, 佑樹
    HiLung Inc.
  • 永元, 哲治
    HiLung Inc.
  • 浅倉, 弘幸
    Tokyo Metropolitan Institute of Public Health
  • 長島, 真美
    Tokyo Metropolitan Institute of Public Health
  • 貞升, 健志
    Tokyo Metropolitan Institute of Public Health
  • 吉村, 和久
    Tokyo Metropolitan Institute of Public Health
  • 上野, 貴将
    Division of Infection and immunity, Joint Research Center for Human Retrovirus infection, Kumamoto University
  • Schreiber, Gideon
    Department of Biomolecular Sciences, Weizmann Institute of Science
  • 高折, 晃史
    Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University
  • 白川, 康太郎
    Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University
  • 澤, 洋文
    Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido University; Division of International Research Promotion, International Institute for Zoonosis Control, Hokkaido University; One Health Research Center, Hokkaido University
  • 入江, 崇
    Graduate School of Biomedical and Health Sciences, Hiroshima University
  • 橋口, 隆生
    Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University
  • 高山, 和雄
    Center for iPS Cell Research and Application (CiRA), Kyoto University; AMED-CREST, Japan Agency for Medical Research and Development (AMED)
  • 松野, 啓太
    One Health Research Center, Hokkaido University; International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University; Division of Risk Analysis and Management, International Institute for Zoonosis Control, Hokkaido University
  • 田中, 伸哉
    Department of Cancer Pathology, Faculty of Medicine, Hokkaido University; Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University
  • 池田, 輝政
    Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus infection, Kumamoto University
  • 福原, 崇介
    Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University; Laboratory of Virus Control, Research Institute for Microbial Diseases, Osaka University
  • 佐藤, 佳
    Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo; Graduate School of Medicine, The University of Tokyo; International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo; International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo; Graduate School of Frontier Sciences, The University of Tokyo; Collaboration Unit for Infection, Joint Research Center for Human Retrovirus infection, Kumamoto University; CREST, Japan Science and Technology Agency

説明

The SARS-CoV-2 Omicron BA.2.75 variant emerged in May 2022. BA.2.75 is a BA.2 descendant but is phylogenetically distinct from BA.5, the currently predominant BA.2 descendant. Here, we show that BA.2.75 has a greater effective reproduction number and different immunogenicity profile than BA.5. We determined the sensitivity of BA.2.75 to vaccinee and convalescent sera as well as a panel of clinically available antiviral drugs and antibodies. Antiviral drugs largely retained potency but antibody sensitivity varied depending on several key BA.2.75-specific substitutions. The BA.2.75 spike exhibited a profoundly higher affinity for its human receptor, ACE2. Additionally, the fusogenicity, growth efficiency in human alveolar epithelial cells, and intrinsic pathogenicity in hamsters of BA.2.75 were greater than those of BA.2. Our multilevel investigations suggest that BA.2.75 acquired virological properties independent of BA.5, and the potential risk of BA.2.75 to global health is greater than that of BA.5.

収録刊行物

被引用文献 (15)*注記

もっと見る

参考文献 (91)*注記

もっと見る

関連プロジェクト

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ